Stipple Bio provides a high‑resolution epitope‑level discovery platform that maps thousands of molecular points on tumor and normal cells to identify tumor‑specific epitopes invisible to conventional antibody discovery. By delivering ultra‑fine epitope maps and comparative analytics, the company enables pharma, biotech, and academic researchers to design more selective oncology antibodies and biologics, expanding target space and accelerating candidate development.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional antibody discovery often focuses on well‑characterized, dominant surface proteins that are shared between healthy and tumor cells, overlooking subtle tumor‑specific epitope differences. This limits the ability to develop truly selective oncology therapeutics and can lead to off‑target effects.
Solution
Stipple Bio applies a high‑resolution, epitope‑level discovery platform that maps thousands of discrete molecular “dots” on tumor and normal cells to reveal tumor‑specific epitopes invisible to traditional methods. By systematically comparing these fine‑grained maps across established, emerging, and novel targets, the platform identifies precise binding sites that are unique to cancer cells. The identified epitopes can be used to design next‑generation antibodies or other biologics with enhanced specificity and safety. Stipple’s approach enables drug developers to expand their target space beyond dominant proteins and accelerate the generation of candidate molecules for clinical development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing oncology biologics, as well as academic research groups seeking highly specific tumor antigens for therapeutic antibody programs.
Features
- Ultra‑high‑resolution epitope mapping that captures thousands of molecular points per target
- Comparative analysis pipeline to pinpoint tumor‑specific epitope differences across multiple cancer types
- Ability to discover epitopes on both well‑studied and previously uncharacterized surface proteins
- Integrated workflow that feeds identified epitopes directly into antibody design and engineering processes
- Proprietary data analytics and visualization tools that present epitope maps in an intuitive, pointillist format for rapid decision‑making